Project Grant R01HL183614
Award Date 9/1/26
Completion Date 4/30/30
Dollars Obligated $903K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $724,200 on July 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate endothelial cell fate switches and dysfunction driven by fibrotic matrix remodeling. The research uses mouse models and an in vitro human microphysiological system of arteriole and venule-scale microvessels embedded within tunable stromal mimetic matrices to demonstrate how fibrotic physical cues...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $414,684 on September 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to establish the Michigan Emergency Medicine Physician-Scientist STARR Training Program. The program recruits and trains emergency medicine resident investigators in research related to heart, lung, blood, and sleep (HLBS) disorders and biological systems, spanning basic, clinical, translational, and...
- The National Heart Lung and Blood Institute awarded Regents of the University of Michigan $771,350 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop an endovascular vortex ultrasound thrombolysis system for treatment of pulmonary embolism. The project will design, fabricate, and characterize a vortex ultrasound transducer integrated into a 9-French catheter to achieve rapid (under 30 minutes) and safe thrombolysis with minimal lytic agent and...
- The National Heart, Lung, and Blood Institute awarded Regents of the University of Michigan $2,257,845 under a Project Grant (R01HL180433) on September 20, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds development of a real-time, non-invasive micro-rheology technique to characterize aging thrombi using ultrasound-responsive nanodroplets. The nanodroplets phase-transition into microbubbles when exposed to focused ultrasound above a threshold amplitude—a...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $1,026,853 on September 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to define the molecular basis of thrombospondin-1-induced fibro-fatty diaphragm remodeling as a driver of obesity-associated respiratory dysfunction. The research investigates how diet-induced obesity promotes diaphragm weakness through fibro-adipogenic progenitor cell expansion and extracellular...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan a $2.858 million Cooperative Agreement under the Cardiovascular Diseases Research program (CFDA 93.837) on September 15, 2026. The University of Michigan will serve as the Clinical Coordinating Center for SPIN VINYL (Systematic Phenotyping and Endotyping in Viral Infections in the Young Lung), a multi-center consortium establishing a harmonized U.S. cohort of 1,500 children aged 0 to 24 months...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $759,670 on August 11, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate metabolite-driven epigenetic regulation in cardiac repair following myocardial infarction. The research examines how disruptions in metabolic pathways deplete critical metabolites—including acetyl-CoA and α-ketoglutarate—required for epigenetic and RNA-modifying enzymes. The project...
- The National Heart Lung and Blood Institute awarded the Regents of the University of Michigan $134,439 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support mentoring in translational interstitial lung disease research. The award funds development of protein-based biomarkers for patients with fibrotic interstitial lung disease (ILD) through two primary objectives: deriving and validating a proteomic biomarker to predict ILD in patients presenting with...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $724,971 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate macrophage 12-lipoxygenase signaling as a therapeutic target in heart failure with preserved ejection fraction (HFPEF). The research program establishes 12-lipoxygenase (12-LOX), an enzyme that converts arachidonic acid into bioactive lipid mediators, as a master regulator of HFPEF progression...
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $773,237 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to examine the adoption, effectiveness, and system-level implications of veno-venous extracorporeal membrane oxygenation (ECMO) for treatment of severe acute respiratory failure. The research combines all-payer utilization data and private payer claims data to characterize ECMO adoption across U.S. hospitals, identify...